- Home
- DTIL
as 07-26-2024 4:00pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 90.7M | IPO Year: | 2019 |
| Target Price: | $46.33 | AVG Volume (30 days): | 33.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.25 - $19.43 | Next Earning Date: | 08-06-2024 |
| Revenue: | $57,531,000 | Revenue Growth: | 88.25% |
| Revenue Growth (this year): | -13.31% | Revenue Growth (next year): | -45.29% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jun 7 '24 | Sell | $11.79 | 50 | $589.50 | 68,559 | SEC Form 4 |
| Scimeca Dario | DTIL | General Counsel and Secretary | Jun 7 '24 | Sell | $11.79 | 93 | $1,096.47 | 6,721 | SEC Form 4 |
| List Alan | DTIL | Chief Medical Officer | May 1 '24 | Sell | $10.32 | 290 | $2,992.80 | 4,488 | SEC Form 4 |
| Scimeca Dario | DTIL | General Counsel and Secretary | May 1 '24 | Sell | $10.32 | 272 | $2,807.04 | 5,680 | SEC Form 4 |
| Amoroso Michael | DTIL | President and CEO | May 1 '24 | Sell | $10.32 | 1,526 | $15,748.32 | 13,772 | SEC Form 4 |
| List Alan | DTIL | Chief Medical Officer | Apr 26 '24 | Sell | $10.03 | 238 | $2,386.43 | 3,796 | SEC Form 4 |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Feb 29 '24 | Sell | $10.32 | 154 | $1,589.28 | 67,613 | SEC Form 4 |
| Amoroso Michael | DTIL | President and CEO | Jan 20 '24 | Sell | $0.36 | 137,390 | $49,460.40 | 356,433 | SEC Form 4 |
| Scimeca Dario | DTIL | General Counsel and Secretary | Jan 20 '24 | Sell | $0.36 | 21,287 | $7,663.32 | 151,028 | SEC Form 4 |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jan 20 '24 | Sell | $0.37 | 28,000 | $10,360.00 | 1,987,269 | SEC Form 4 |
| List Alan | DTIL | Chief Medical Officer | Jan 20 '24 | Sell | $0.36 | 21,526 | $7,749.36 | 94,982 | SEC Form 4 |
| Scimeca Dario | DTIL | General Counsel and Secretary | Nov 2 '23 | Sell | $0.40 | 16,023 | $6,409.20 | 112,970 | SEC Form 4 |
| Kelly John Alexander | DTIL | Chief Financial Officer | Aug 18 '23 | Buy | $0.48 | 90,000 | $43,200.00 | 383,340 | SEC Form 4 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Business Wire
19 days ago
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
Business Wire
a month ago
Precision BioSciences Announces its Addition to the Russell Microcap® Index
Business Wire
a month ago
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Business Wire
a month ago
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
Business Wire
2 months ago
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Business Wire
2 months ago
Precision BioSciences to Participate in Upcoming June Investor Conferences
Zacks
2 months ago
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
Business Wire
2 months ago
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.